Investigational new drugs for the treatment of resistant pneumococcal infections

被引:27
作者
Hoffman-Roberts, HL [1 ]
Babcock, EC [1 ]
Mitropoulos, IF [1 ]
机构
[1] Coll Pharm, Oklahoma City, OK 73190 USA
关键词
ceftobiprole; dalbavancin; faropenem; garenoxacin; investigational antibiotics; oritavancin; pneumonia; resistance; RWJ-442831; sitafloxacin; Streptococcus pneumoniae;
D O I
10.1517/13543784.14.8.973
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Antibiotic resistance in Streptococcus pneumoniae is not only increasing with penicillin but also with other antimicrobial classes including the macrolides, tetracyclines and sulfonamides. This trend with antibiotic resistance has highlighted the need for the further development of new anti-infectives for the treatment of pneumococcal infections, particularly against multi-drug resistant pneumococci. Several new drugs with anti-pneumococcal activity are at various stages of development and will be discussed in this review. Two new cephalosporins with activity against S. pneumoniae include ceftobiprole and RWJ-54428. Faropenem is in a new class of beta-lactam antibiotics called the penems. Structurally, the penems are a hybrid between the penicillins and cephalosporins. Sitafloxacin and garenoxacin are two new quinolones that are likely to have a role in treating pneumococcal infections. Oritavancin and dalbavancin are glycopeptides with activity against methicillin-resistant S. aureus and vancomycin-resistant Enterococcus spp. as well as multi-drug resistant pneumococci. Tigecycline is the first drug in a new class of anti-infectives called the glycycyclines that has activity against penicillin-resistant pneumococci.
引用
收藏
页码:973 / 995
页数:23
相关论文
共 120 条
[1]   Characterization of the penetration of garenoxacin into the breast milk of lactating women [J].
Amsden, GW ;
Nicolau, DP ;
Whitaker, AM ;
Maglio, D ;
Bello, A ;
Russo, R ;
Barros, A ;
Gajjar, DA .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (02) :188-192
[2]   Pharmacodynamics of the new des-F(6)-quinolone garenoxacin in a murine thigh infection model [J].
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) :3935-3941
[3]   Antimicrobial treatment guidelines for acute bacterial rhinosinusitis - Executive summary [J].
Anon, JB ;
Jacobs, MR ;
Roche, R ;
Poole, MD ;
Merck, D ;
Ambrose, PG ;
Benninger, MS ;
Hadley, JA ;
Craig, WA ;
Andes, DR ;
Bernstein, JM ;
Besser, RE ;
Dowell, SF ;
Drusano, GL ;
Klepser, ME ;
Nicolau, D ;
Radowsky, A ;
Reller, LB ;
Wald, ER ;
Zucker, DR .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2004, 130 (01) :1-45
[4]  
[Anonymous], 2003, 43 INT C ANT AG CHEM
[5]   Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia [J].
Azoulay-Dupuis, E ;
Bédos, JP ;
Mohler, J ;
Schmitt-Hoffmann, A ;
Schleimer, M ;
Shapiro, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1105-1111
[6]  
BELLO A, 2001, 41 INT C ANT AG CHEM
[7]   Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects [J].
Bhavnani, SM ;
Owen, JS ;
Loutit, JS ;
Porter, SB ;
Ambrose, PG .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 50 (02) :95-102
[8]   Effect of protein binding on the in vitro activity and pharmacodynamics of faropenem [J].
Boswell, FJ ;
Ashby, JP ;
Andrews, JM ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (04) :525-532
[9]   Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002 [J].
Brown, SD ;
Farrell, DJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 :I23-I29
[10]  
BRYSKIER A, 1995, EXPERT OPIN INV DRUG, V4, P705